Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.

Zhang, Yuhui; Stewart Coats, Andrew J; Zheng, Zhe; Adamo, Marianna; Ambrosio, Giuseppe; Anker, Stefan D; Butler, Javed; Xu, Dingli; Mao, Jingyuan; Khan, Muhammad Shahzeb; Bai, Ling; Mebazaa, Alexandre; Ponikowski, Piotr; Tang, Qizhu; Ruschitzka, Frank; Seferovic, Petar; Tschöpe, Carsten; Zhang, Shuyang; Gao, Chuanyu; Zhou, Shenghua; Senni, Michele; Zhang, Jian; Metra, Marco

The Coronavirus Disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and United States. This article is protected by copyright. All rights reserved.